Holen Sie sich die Stockscreener-App
4.59
2.55%
-0.12
Handel nachbörslich:
4.59
Schlusskurs vom Vortag:
$4.71
Offen:
$4.71
24-Stunden-Volumen:
51,349
Relative Volume:
0.14
Marktkapitalisierung:
$37.54M
Einnahmen:
$120.77M
Nettoeinkommen (Verlust:
$32.69M
KGV:
1.5748
EPS:
2.9146
Netto-Cashflow:
$-50.94M
1W Leistung:
-6.52%
1M Leistung:
-15.31%
6M Leistung:
-66.59%
1J Leistung:
-33.28%
1-Tages-Spanne:
$4.585
$4.9899
1-Wochen-Bereich:
$4.585
$5.35
52-Wochen-Spanne:
$3.92
$19.14
Atara Biotherapeutics Inc Stock (ATRA) Company Profile
Firmenname
Atara Biotherapeutics Inc
Sektor
Branche
Telefon
805-623-4211
Adresse
1280 RANCHO CONEJO BLVD, THOUSAND OAKS, CA
Compare ATRA vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ATRA
Atara Biotherapeutics Inc
|
4.59 | 37.54M | 120.77M | 32.69M | -50.94M | 2.9146 |
VRTX
Vertex Pharmaceuticals Inc
|
433.07 | 110.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
737.71 | 77.99B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
691.40 | 42.91B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
317.36 | 42.09B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
283.03 | 31.42B | 5.36B | 287.73M | 924.18M | 2.5229 |
Atara Biotherapeutics Inc Stock (ATRA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-13 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2023-11-09 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2023-11-09 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2023-11-09 | Herabstufung | Mizuho | Buy → Neutral |
| 2022-07-20 | Herabstufung | Citigroup | Neutral → Sell |
| 2022-07-13 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2022-07-13 | Herabstufung | Stifel | Buy → Hold |
| 2022-05-10 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-05-13 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-12-09 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-12-08 | Bestätigt | H.C. Wainwright | Buy |
| 2020-11-10 | Bestätigt | H.C. Wainwright | Buy |
| 2020-06-30 | Eingeleitet | Evercore ISI | Outperform |
| 2020-06-15 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-04-23 | Hochstufung | Citigroup | Neutral → Buy |
| 2019-11-08 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2019-09-27 | Herabstufung | Goldman | Neutral → Sell |
| 2019-09-16 | Herabstufung | Jefferies | Buy → Hold |
| 2019-06-04 | Hochstufung | Citigroup | Sell → Neutral |
| 2019-05-30 | Eingeleitet | ROTH Capital | Buy |
| 2019-05-23 | Eingeleitet | Stifel | Buy |
| 2019-01-23 | Eingeleitet | Mizuho | Buy |
| 2018-04-10 | Eingeleitet | JP Morgan | Overweight |
| 2018-03-16 | Eingeleitet | Guggenheim | Neutral |
| 2018-03-05 | Bestätigt | Jefferies | Buy |
| 2018-02-28 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2018-02-15 | Herabstufung | Citigroup | Neutral → Sell |
| 2018-01-03 | Hochstufung | Citigroup | Sell → Neutral |
| 2017-10-06 | Fortgesetzt | Goldman | Neutral |
Alle ansehen
Atara Biotherapeutics Inc Aktie (ATRA) Neueste Nachrichten
ATRA UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Atara Biotherapeutics (ATRA) Investors of Securities Class Action Deadline on May 22, 2026 - PR Newswire
ROSEN, LEADING INVESTOR COUNSEL, Encourages Atara - GlobeNewswire
FinancialContentLaw Offices of Howard G. Smith Encourages Atara Biotherapeutics, Inc. (ATRA) Shareholders To Inquire About Securities Fraud Class Action - FinancialContent
Bragar Eagel & Squire, P.C. Announces that a Class Action - GlobeNewswire
ATRA Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Atara ... - Bluefield Daily Telegraph
ATRA Shareholder Alert: Investors With Losses May Seek to - GlobeNewswire
ATRA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Atara Biotherapeutics, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
ATRA Class Action ReminderRobbins LLP Reminds Investors - GlobeNewswire
Securities Fraud Investigation Into Atara Biotherapeutics, Inc. (ATRA) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm - The AI Journal
Bronstein, Gewirtz & Grossman LLC Urges Atara - GlobeNewswire
Pomerantz Law Firm Announces the Filing of a Class Action Against Atara Biotherapeutics, Inc. and Certain OfficersATRA - PR Newswire
[EFFECT] Atara Biotherapeutics, Inc. SEC Filing - stocktitan.net
ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - businesswire.com
ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Atara Biotherapeutics, Inc. Investors to Secure ... - Caledonian Record
Securities Fraud Investigation Into Atara Biotherapeutics, Inc. (ATRA) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz - The AI Journal
Atara Biotherapeutics (ATRA) registers 400,000 shares for resale by HCR - stocktitan.net
Portnoy Law Firm Announces Class Action on Behalf of Atara Biotherapeutics, Inc. Investors - GlobeNewswire
Drug Co. Atara Hit With Investor Suit Over FDA Denial - Law360
INVESTOR ALERT: Securities Class Action Filed Against Atara Biotherapeutics, Inc. – Investors Encouraged to Contact Kirby McInerney LLP - The AI Journal
ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit - The Daily Tribune News
ATRA Investor Alert: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Lawsuit Against Atara Biotherapeutics, Inc. - PR Newswire
Rosen Law Firm Urges Atara Biotherapeutics, Inc. (NASDAQ: ATRA) Stockholders to Contact the Firm for Information About Their Rights - The AI Journal
INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of - GlobeNewswire
Stockholder Notice: Robbins LLP Informs Investors of the Atara Biotherapeutics, Inc. Class Action Lawsuit - The AI Journal
ATRA DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Atara Biotherapeutics (ATRA) Investors of ... - Bluefield Daily Telegraph
ATRA DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Atara - GlobeNewswire
Panacea entities boost Atara (ATRA) stake via 259,163-share warrant exercise - stocktitan.net
What are analysts price targets for Atara Biotherapeutics Inc2026 Valuation Update & Breakout Confirmation Alerts - baoquankhu1.vn
Form S-3 Atara Biotherapeutics Inc For: 18 March By Investing.com - Investing.com Australia
[S-3] Atara Biotherapeutics, Inc. Shelf Registration Statement | ATRA SEC FilingForm S-3 - Stock Titan
Market Recap: Will Atara Biotherapeutics Inc benefit from AI trendsEarnings Trend Report & Weekly Momentum Stock Picks - baoquankhu1.vn
Atara schedules FDA meeting on tabelecleucel license application - Investing.com Nigeria
Atara Biotherapeutics, Inc. 2025 Annual Report: Strategic Alternatives, Business Overview, and Risk Factors - Minichart
Form 424B5 Atara Biotherapeutics Inc For: 16 March By Investing.com - Investing.com Australia
Atara Biotherapeutics: Q4 Loss & Annual Profit 2025 Financial ResultsNews and Statistics - IndexBox
Atara Biotherapeutics: Q4 Earnings Snapshot - Barchart
Atara Biotherapeutics (NASDAQ: ATRA) registers $11.1M ATM offering via TD Cowen - Stock Titan
Atara Biotherapeutics (ATRA) bets on tab-cel as layoffs, FDA pushback mount - Stock Titan
Atara (NASDAQ: ATRA) turns 2025 profit and targets cash runway into 2026 - Stock Titan
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Operational Progress - The Joplin Globe
Atara Biotherapeutics: Fourth Quarter Earnings Overview - Bitget
Atara Biotherapeutics, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Prasad’s rule by fiat spilled into accelerated approvals in hematology and oncology Atara Bio’s Cokey Nguyen: Normally, FDA wants to help us succeed. Now, “we’re getting new guidance at the last minute and it’s not helping.” - The Cancer Letter
Weekly Trades: Will Atara Biotherapeutics Inc benefit from AI trendsQuarterly Market Review & Stock Portfolio Risk Management - baoquankhu1.vn
Atara schedules FDA meeting on tabelecleucel license application By Investing.com - Investing.com South Africa
Atara Biotherapeutics Inc Provides Regulatory Update on Tabelecleucel - marketscreener.com
Precision Trading with Atara Biotherapeutics Inc. (ATRA) Risk Zones - Stock Traders Daily
Atara (ATRA) Schedules FDA Meeting to Address CRL for Tabelecleu - GuruFocus
Atara Plans FDA Type A Meeting on EBVALLO - TipRanks
Atara Biotherapeutics schedules FDA Type A meeting on EBVALLO BLA complete response - TradingView
FDA to hold Type A meeting on Atara Biotherapeutics (ATRA) EBVALLO tab-cel BLA - Stock Titan
Finanzdaten der Atara Biotherapeutics Inc-Aktie (ATRA)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.03%
2.20%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):